(Q35108992)

6 August 2017

1 reference

title

Selective estrogen receptors modulators in the prevention and treatment of postmenopausal osteoporosis (English)

1 reference

postmenopausal osteoporosis

6 August 2017

1 reference

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(02)00057-9

24 December 2023

2

Pierre D. Delmas

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12699300

24 December 2023

author name string

Aurelie Fontana

series ordinal

1

1 reference

6 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12699300

24 December 2023

publication date

1 March 2003

1 reference

full work available at URL

6 August 2017

https://api.elsevier.com/content/article/PII:S0889852902000579?httpAccept=text/xml

1 reference

DOI

https://api.crossref.org/works/10.1016/S0889-8529(02)00057-9

https://api.elsevier.com/content/article/PII:S0889852902000579?httpAccept=text/plain

24 December 2023

1 reference

DOI

https://api.crossref.org/works/10.1016/S0889-8529(02)00057-9

Endocrinology and Metabolism Clinics of North America

24 December 2023

published in

1 reference

6 August 2017

32

1 reference

6 August 2017

1

1 reference

6 August 2017

219-232

1 reference

The effect of postmenopausal estrogen therapy on bone density in elderly women

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900057-9

7 January 2021

Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900057-9

7 January 2021

Hormone replacement therapy in relation to breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900057-9

7 January 2021

Dual-energy x-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900057-9

7 January 2021

Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900057-9

7 January 2021

Recovery of proximal tibia bone mineral density and strength, but not cancellous bone architecture, after long-term bisphosphonate or selective estrogen receptor modulator therapy in aged rats

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900057-9

7 January 2021

Effects of tamoxifen and toremifene on urinary excretion of pyridinoline and deoxypyridinoline and bone density in postmenopausal patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900057-9

7 January 2021

A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900057-9

7 January 2021

Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900057-9

7 January 2021

Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900057-9

7 January 2021

Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900057-9

7 January 2021

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900057-9

7 January 2021

A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900057-9

7 January 2021

Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900057-9

7 January 2021

Effects of tamoxifen on spinal bone density in women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900057-9

7 January 2021

Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900057-9

7 January 2021

Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900057-9

7 January 2021

Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900057-9

7 January 2021

Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900057-9

7 January 2021

The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900057-9

7 January 2021

The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900057-9

7 January 2021

Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900057-9

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900057-9

7 January 2021

Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900057-9

7 January 2021

Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900057-9

7 January 2021

Design and methods of the Raloxifene Use for The Heart (RUTH) study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900057-9

7 January 2021

Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900057-9

7 January 2021

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900057-9

7 January 2021

Adverse events reported by postmenopausal women in controlled trials with raloxifene

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900057-9

7 January 2021

Tamoxifen in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900057-9

7 January 2021

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900057-9

7 January 2021

Cognitive function in postmenopausal women treated with raloxifene

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900057-9

7 January 2021

Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900057-9

7 January 2021

A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900057-9

7 January 2021

Identifiers

DOI

1 reference

6 August 2017

1 reference